Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

395
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
395
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

496
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
496
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

428
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
428
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

224
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
224
Cytoskeletal Linker Proteins - Plakins01:09

Cytoskeletal Linker Proteins - Plakins

2.8K
Plakins are large proteins with binding domains for microtubules, microfilaments, intermediate filaments, and membrane-associated protein complexes at cell junctions. Plakin functions are evolutionarily conserved and are primarily involved in organizing the different components of the cytoskeleton by crosslinking them to each other and connecting them to the cell-matrix and cell adhesion complexes. They are also known to interact with signal transducers, serve as scaffolds for signaling...
2.8K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

416
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
416

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanical Loading Induces Distinct and Shared Responses in Endothelial and Muscle Cells and Reveals Exercise-Like Molecular Profiles.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same author

Prebiotic xylo-oligosaccharides cause modest taxonomic shifts in the gut microbiota but do not increase insulin sensitivity in insulin resistant individuals.

Nutrition & metabolism·2026
Same author

Macrophage recruitment is a hallmark of non-syndromic myxomatous mitral valve disease.

Cardiovascular research·2026
Same author

Unsupervised machine learning analysis to enhance risk stratification in patients with asymptomatic aortic stenosis.

European heart journal. Digital health·2026
Same author

Mechanotransduction as an emerging pathophysiological determinant of cardiovascular diseases.

Cardiovascular research·2025
Same author

Programmable Assembly of Multistranded Helices in Water.

Nature communications·2025

Related Experiment Video

Updated: Jan 19, 2026

Detection of Nuclear Blebbing and DNA Leakage in Mammalian Cells by Immunofluorescence
06:23

Detection of Nuclear Blebbing and DNA Leakage in Mammalian Cells by Immunofluorescence

Published on: January 17, 2025

1.2K

Critical Structural Defects Explain Filamin A Mutations Causing Mitral Valve Dysplasia.

Tatu J K Haataja1, Romain Capoulade2, Simon Lecointe2

  • 1Department of Biological and Environmental Science and Nanoscience Center, University of Jyväskylä, Jyväskylä, Finland; Institute of Biomedicine, University of Turku, Turku, Finland; Turku Bioscience Centre, University of Turku, 20520 Turku, Finland.

Biophysical Journal
|September 23, 2019
PubMed
Summary

Genetic mutations in the filamin A gene (FLNA) cause mitral valve dysplasia (MVD). Specific FLNA mutations disrupt protein folding and interactions, impacting cardiac development and offering targets for new therapies.

More Related Videos

A Pipeline to Characterize Structural Heart Defects in the Fetal Mouse
08:19

A Pipeline to Characterize Structural Heart Defects in the Fetal Mouse

Published on: December 16, 2022

2.4K
Preparation of 3D Decellularized Matrices from Fetal Mouse Skeletal Muscle for Cell Culture
07:44

Preparation of 3D Decellularized Matrices from Fetal Mouse Skeletal Muscle for Cell Culture

Published on: March 3, 2023

1.8K

Related Experiment Videos

Last Updated: Jan 19, 2026

Detection of Nuclear Blebbing and DNA Leakage in Mammalian Cells by Immunofluorescence
06:23

Detection of Nuclear Blebbing and DNA Leakage in Mammalian Cells by Immunofluorescence

Published on: January 17, 2025

1.2K
A Pipeline to Characterize Structural Heart Defects in the Fetal Mouse
08:19

A Pipeline to Characterize Structural Heart Defects in the Fetal Mouse

Published on: December 16, 2022

2.4K
Preparation of 3D Decellularized Matrices from Fetal Mouse Skeletal Muscle for Cell Culture
07:44

Preparation of 3D Decellularized Matrices from Fetal Mouse Skeletal Muscle for Cell Culture

Published on: March 3, 2023

1.8K

Area of Science:

  • Cardiovascular Biology
  • Genetic Medicine
  • Structural Biology

Background:

  • Mitral valve diseases affect 3% of the population, commonly requiring surgery due to lack of drug treatments.
  • Inheritable genetic mutations, specifically in the filamin A gene (FLNA), are identified as causes of mitral valve insufficiency.
  • FLNA protein is crucial for cardiac development, particularly in fetal valve formation.

Purpose of the Study:

  • To investigate the structural and functional consequences of FLNA mutations causing mitral valve dysplasia (MVD).
  • To elucidate the molecular mechanisms underlying FLNA-MVD pathogenesis.

Main Methods:

  • Nuclear Magnetic Resonance (NMR) spectroscopy to analyze protein structure.
  • Interaction assays to assess protein binding capabilities.
  • Investigation of specific FLNA mutations (V711D and H743P).

Main Results:

  • FLNA mutations V711D and H743P severely disrupt the folding of the FLNA5 domain and affect the FLNA4 domain.
  • The FLNA6 domain structure remained unaffected by the studied mutations.
  • Mutations abolished FLNA's interaction with protein tyrosine phosphatase nonreceptor type 12, a key factor in FLNA-MVD.

Conclusions:

  • The study provides a structural and molecular basis for understanding FLNA-MVD.
  • Findings are critical for developing novel therapeutic strategies beyond surgical intervention.